Announcements Trials

Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 6 Observational 1

Sponsor

Conditions

Prostatic Neoplasms 1 Patient Satisfaction 1 Neuromuscular Junction Diseases 1 Nervous System Diseases 1 Neoplasms 1 Myasthenia Gravis 1 Muscle Weakness 1 Immune System Diseases 1 COVID-19 1 Autoimmune Diseases of the Nervous System 1 Autoimmune Diseases 1

Interventions

Surveys and Questionnaires 86 Blood Specimen Collection 58 Interviews as Topic 28 Observation 15 Data Collection 15 Radiotherapy 12 Watchful Waiting 11 Magnetic Resonance Spectroscopy 11 Hematologic Tests 11 Exercise 11 Drug Therapy 11 Quality of Life 9 Biopsy 8 Specimen Handling 7 Therapeutics 6 Restraint, Physical 6 Magnetic Resonance Imaging 6 Focus Groups 6 pembrolizumab 5 Standard of Care 5 Rivaroxaban 5 Phlebotomy 5 Nivolumab 5 Lapatinib 5 Immune Checkpoint Inhibitors 5 atezolizumab 4 apixaban 4 Trastuzumab 4 Patient Reported Outcome Measures 4 Palliative Care 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Neoplasms × Telemedicine × Clear all

NCT04357574 2026-02-06

CORONA-SHIELD

Duke University

Enrolling by invitation

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡